

18 August 2016

September 2016 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **September 2016** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings

- Amisulpride (Sulprix) tab 100 mg (p'code 2500132), 200 mg (p'code 2500140) and 400 mg (p'code 2500159) – Safety medicine
- Atorvastatin (Lorstat) tab 10 mg (p'code 2493586), 20 mg (p'code 2493594), 40 mg (p'code 2493608) and 80 mg (p'code 2493616)
- Cefalexin (Cephalexin ABM) cap 250 mg (p'code 2498871)
- Ceftriaxone (DEVA) inj 500 mg vial (p'code 2504952) and 1 g vial (p'code 2504960) – subsidy by endorsement, up to 5 inj available on a PSO
- Clobetasol propionate (Dermol) crm 0.05%, 30 g OP (p'code 229059) and oint 0.05%, 30 g OP (p'code 229040)
- Dextrose with electrolytes (Pedialyte – Bubblegum) soln with electrolytes (2 x 500 ml), 1,000 ml OP (p'code 2504308)
- Pembrolizumab inj 50 mg vial (Keytruda) (p'code 2489023) and inj 1 mg for ECP (Baxter) (p'code 2508427) – PCT only – Specialist – Special Authority
- Posaconazole (Noxafil) tab modified-release 100 mg – Special Authority – Retail pharmacy (p'code 2490811)
- Zoledronic acid (Zoledronic acid Mylan) inj 4 mg per 5 ml, vial – Special Authority – Retail pharmacy (p'code 2503360)

Changes to restrictions, chemical names and presentations

- Enoxaparin sodium (Clexane) inj syringes 20 mg in 0.2 ml, 40 mg in 0.4 ml, 60 mg in 0.6 ml, 80 mg in 0.8 ml, 100 mg in 1 ml, 120 mg in 0.8 ml and 150 mg in 1 ml – amended presentation description
- Ipratropium bromide (Atrovent) aerosol inhaler, 20 mcg per dose CFC-free – addition of 400 doses available on a PSO
- Metoprolol succinate (Metoprolol – AFT CR, Actavis-Metoprolol, Betaloc CR, and Myloc CR) – tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg – Brand Switch Fee removed
- Nivolumab inj 10 mg per ml, 4 ml and 10 ml vial (Opdivo) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Temozolomide (Temaccord) cap 5 mg, 20 mg, 100 mg and 250 mg – amended Special Authority criteria

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Alginic acid	Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet	Gaviscon Infant
Clotrimazole	Vaginal crm 1% with applicators, 35 g OP	Clomazol
Pyridostigmine bromide	Tab 60 mg	Mestinon

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Clotrimazole	Vaginal crm 2% with applicators, 20 g OP	Clomazol	
Dabigatran	Cap 75 mg, 110 mg & 150 mg	Pradaxa	
Enoxaparin sodium	Inj syringe 20 mg in 0.2 ml, 40 mg in 0.4 ml, 60 mg in 0.6 ml, 80 mg in 0.8 ml, 100 mg in 1 ml, 120 mg in 0.8 ml & 150 mg in 1 ml	Clexane	
Levomepromazine hydrochloride	Inj 25 mg per ml, 1 ml ampoule	Wockhardt*	Nozinan
Mesna	Inj 100 mg per ml, 4 ml & 10 ml ampoules	Uromitexan	
Oxycodone hydrochloride	Tab controlled-release 5 mg	BNM*	OxyContin
Oxycodone hydrochloride	tab controlled-release 10 mg, 20 mg, 40 mg & 80 mg	BNM*	Oxycodone Controlled Release Tablets (BNM)
Sertraline	Tab 50 mg, 30 tab pack	Sertraline Actavis S29*	Sertraline Actavis
Tenoxicam	Tab 20 mg	Reutenox Tenoxicam*	

* no subsidy changes for these brands for 1 September 2016.